Morrison, Lester M.; Enrick, Norbert L.
May 1973
Angiology;May1973, Vol. 24 Issue 5, p269
Academic Journal
1. One hundred twenty patients with proven coronary heart disease were divided into two comparable random-selected groups of 60 patients each, and were studied over a six year period for the development or recurrence of coronary incidents. 2. Coronary incidents consisted of proven, documented a) fatal myocardial infarctions, b) non-fatal myocardial infarctions, c) acute coronary insufficiency requiring hospitalization in coronary or intensive care units of general hospitals, d) acute myocardial ischemia requiring hospitalization and treatment in a general hospital. 3. Sixty patients received oral chondroitin sulfate A (CSA) daily for six years with conventional treatment. Sixty patients received no CSA but comparable conventional treatment over the six year period. Six coronary incidents in CSA treated were observed as compared to 42 in non-CSA treated patients or a ratio of 6:42. 4. Four fatal myocardial infarctions were observed in the CSA treated group of patients as compared to 14 fatal myocardial infarctions in the control, non-CSA treated patients; a ratio of 4:14 for cardiac death rate. 5. No adverse clinical effects or abnormal laboratory findings were found from CSA administration over six years. 6. Statistical analysis of the raw patient data reveals a statistical significance for possibility of error of less than 0.001 for therapeutic efficacy of CSA on the prevention of coronary incidents, and less than 0.1% for coronary death rate.


Related Articles

  • Infarct angioplasty: beyond stents and glycoprotein llb/llla inhibitors. Dixon, S. R. // Heart;Jun2005 Supplement 3, Vol. 91, piii2 

    The article reports that although extraordinary advances have been made in the treatment of acute myocardial infarction, new approaches are required, beyond stents and glycoprotein IIb/IIIa inhibitors, to improve clinical outcome for these patients. At present, the major focus of clinical...

  • Stimulation of collateral artery growth: travelling further down the road to clinical application. S H Schirmer // Heart;Feb2009, Vol. 95 Issue 3, p191 

    Collateral artery growth is a potent natural defence mechanism to prevent death and myocardial infarction in occlusive artery disease. Given the high prevalence of arterial obstructive disease, a therapeutic compound stimulating collateral vessel growth could have a major impact on morbidity and...

  • Granulocyte colony-stimulating factor and stem cell factor improve endogenous repair after myocardial infarction. Kanellakis, Peter; Slater, Nicholas J.; Du, Xiao-Jun; Bobik, Alex; Curtis, David J. // Cardiovascular Research;Apr2006, Vol. 70 Issue 1, p117 

    Abstract: Objective: The aims of this study were, first, to determine if granulocyte colony-stimulating factor (G-CSF) and stem cell factor (SCF) improved left ventricular function in the setting of a reperfusion model of myocardial infarction (MI) and, second, to evaluate the effects of...

  • THE HAPPY TOWN WHERE HEARTS STAY HEALTHY. Massie, Robert K. // Saturday Evening Post;10/10/1964, Vol. 237 Issue 35, p76 

    The article presents a study on myocardial infraction that was conducted in Roseto, Pennsylvania, to find out the causes of low incidence of heart attack among the people of the town. The study was conducted by Stewart Wolf, professor of medicine at the University of Oklahoma. The first...

  • Us and them: Coronary heart disease.  // Medeconomics;Dec2003, Vol. 24 Issue 12, p23 

    Coronary heart disease (CHD) is the most prevalent fatal disease among Great Britain working male population, accounting for about 14 per cent of working years of life lost to men dying prematurely in England and Wales. CHD is largely responsible for higher mortality rate in Great Britain,...

  • Take heart: Targeted intervention shows results. Condon, Deborah // World of Irish Nursing & Midwifery;Feb2006, Vol. 14 Issue 2, p26 

    The article focuses on the national heartwatch program which has aimed at reducing morbidity and mortality in Ireland. The country has hold the title of the highest coronary heart disease death rate within the European Union. This heartwatch program has been considered as one of the most...

  • Levosimendan improves hemodynamics and coronary flow reserve after percutaneous coronary intervention in patients with acute myocardial infarction and left ventricular dysfunction.  // Current Medical Literature: Interventional Cardiology Monitor;2006, Vol. 13 Issue 1, p20 

    Discusses research being done on the effect of levosimendan on coronary hemodynamics in the context of acute myocardial infarction associated with left ventricular dysfunction. Reference to a study by L. De Luca and colleagues which appeared in a 2005 issue of the "American Heart Journal";...

  • Clinical: Journals Watch - Heart failure, smoking and diabetes. Hunter, Suzanne // GP: General Practitioner;4/16/2010, p28 

    The article discusses studies related to medicine research which were published in various journals. A study published in a 2010 issue of the journal "Heart" found that the use of oxygen in uncomplicated myocardial infarction (MI) may actually lead to increased infarct size and worse mortality....

  • …and how many angioplasties?  // Cortlandt Forum;Jan2007, Vol. 20 Issue 1, p14 

    The article reports on a research on medical practices in using angioplasty after three days to patients with heart failure. This procedure is not efficient and could even cause harm. The study concluded that percutaneous coronary intervention did not reduce the occurrence and risk of this...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics